New Study Looks at the Top Biotech Deals & IPOs of 2016
The RSA Group has published the latest of its Talent Equity® Reports, an analysis of biotech deals and IPOs in 2016.
A challenging year for the biotech sector, this report focuses on those CEOs and CFOs whose companies were outstanding in performing better than their peers in either IPOs or deal-making. By comparing CEOs and CFOs across 10 separate measures, we look at the factors that have combined to enable them to stand out and succeed.
Executive Chairman, Nick Stephens said “….it’s the talent of the people that enables the wise use of investors’ funds to advance the science. So what is it about the best of these company leaders that makes them so successful? What characteristics do they have that give them the edge over their competitors?”